Allarity Therapeutics, Inc. filed a current report on Form 8-K on October 30, 2026, disclosing the termination, effective October 28, 2026, of its Common Stock Purchase Agreement with Tumim Stone Capital LLC.

Key Highlights

  • Agreement terminated: The Common Stock Purchase Agreement, originally dated January 28, 2026, between Allarity Therapeutics and Tumim Stone Capital LLC was terminated effective October 28, 2026.
  • Facility size: The agreement had provided the company the right to sell up to $6.0 million of newly issued common stock to Tumim at its sole discretion.
  • No termination penalty: According to the filing, no early termination penalty is payable in connection with the termination.
  • Reason cited: The company stated it elected to terminate "in connection with its plans to pursue alternative financing arrangements."
  • Surviving provisions: Indemnification and certain expense obligations under the Purchase Agreement remain in effect in accordance with their terms following termination.
  • No further sales: Following the termination, the company disclosed it will not sell any additional shares of common stock to Tumim under the agreement.

Allarity Therapeutics Ends Equity Line with Tumim Stone Capital

Allarity Therapeutics, Inc. (NASDAQ:ALLR) disclosed the termination of its Common Stock Purchase Agreement with Tumim Stone Capital LLC, according to an Item 1.02 filing reporting the end of a material definitive agreement. The termination was effective October 28, 2026, the date of earliest event reported in the filing.

The now-terminated agreement, originally dated January 28, 2026, gave the company the right, but not the obligation, to sell up to $6.0 million of newly issued shares of common stock, par value $0.0001 per share, to Tumim from time to time at the company's sole discretion. The filing noted that the purchase price for each sale was determined under a formula based on the volume-weighted average price of the common stock during the applicable pricing period. The shares had been registered under a Form S-3 registration statement (File No. 333-291906) pursuant to a prospectus supplement dated January 28, 2026.

The company disclosed that no early termination penalty is payable under the Purchase Agreement. Certain provisions, specifically indemnification and certain expense obligations, expressly survive the termination and remain in effect according to their terms. The original Purchase Agreement had been filed as Exhibit 10.1 to the company's Form 8-K submitted to the SEC on January 29, 2026. The filing was signed by Thomas H. Jensen, Chief Executive Officer, on October 30, 2026.

What Was Disclosed

Allarity Therapeutics reported the October 28, 2026 termination of its $6.0 million Common Stock Purchase Agreement with Tumim Stone Capital LLC, citing plans for alternative financing, with no early termination penalty and certain provisions surviving termination.